To include your compound in the COVID-19 Resource Center, submit it here.

Catena idebenone: Extension study data

Data from 68 patients in the open-label IONIA-E extension study of the Phase III IONIA trial showed that the subgroup that received high-dose Catena for 18 months (n=22) significantly improved neurological

Read the full 311 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE